The global pharma industry experienced an 11% rise in social media posts on big data in Q1 2023 compared with the previous quarter, with the highest share accounted for Eli Lilly and Co, according to GlobalData’s analysis of social media posts. The big data landscape is rapidly evolving and pharma companies are increasingly integrating big data analytics into their value chains. GlobalData’s Big Data in Pharmaceuticals – Thematic Research report offers an overview of the current landscape, trends, and leading companies, and highlights the opportunities for the use of big data analytics in the future. Buy the report here.
Notably, Covid-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions ahead of orphan designated drugs and innovation, according to GlobalData.
Of the 50 leading companies in the pharma industry, Regeneron Pharmaceuticals had the most mentions of big data in Q1 2023. GlobalData identified 450 big data-related posts in the industry's social media activity - 0.03% of all posts - and an increase of 11% in Q1 2023 compared with Q4 2022.
For further understanding of GlobalData's Big Data in Pharmaceuticals - Thematic Research buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.